A multi-center, double-phase, randomized, double-blind, placebo controlled (12-week double-blind followed by 12-week open-label) study evaluating the effect of tolterodine ER on urgency urinary incontinence (UUI), urgency, frequency, sexual quality of life and sexual function in women with overactive bladder

Trial Profile

A multi-center, double-phase, randomized, double-blind, placebo controlled (12-week double-blind followed by 12-week open-label) study evaluating the effect of tolterodine ER on urgency urinary incontinence (UUI), urgency, frequency, sexual quality of life and sexual function in women with overactive bladder

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2013

At a glance

  • Drugs Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2008 Results published in 'International Urogynecology Journal'.
    • 10 Aug 2006 Status change
    • 06 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top